At a glance
What is it—and why does it matter?
An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
Follistatin (human) is described as a regulatory glycoprotein, indicating a protein with regulatory biological roles.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Human follistatin is a regulatory glycoprotein”
An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential. · Abstract
pubmed:23249626:bdc9f4ba1d68:bdc9f4ba1d68
How does it work?
Target, response, and disposition.
Mechanism
Follistatin is described as a myostatin-inhibiting protein (i.e., it inhibits myostatin activity).
2 cited sources · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 2 source records. 2 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Follistatin, a myostatin-inhibiting protein,”
Detection of black market follistatin 344. · Abstract
pubmed:31758732:f5e4ca131d7e:f5e4ca131d7e - supports · Source-backed record
“Activin A is an autocrine inhibitor of cell growth in the liver.”
Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats. · BACKGROUND/AIMS
pubmed:15782995:ca9c7c75937e:ca9c7c75937e - supports · Source-backed record
“The biological activity of activin A is mediated by a heteromeric receptor complex.”
Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats. · BACKGROUND/AIMS
pubmed:15782995:ca9c7c75937e:ca9c7c75937e - supports · Source-backed record
“Follistatin (FS) binds to activin and inhibits its biological effects”
Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats. · BACKGROUND/AIMS
pubmed:15782995:ca9c7c75937e:ca9c7c75937e - supports · Source-backed record
“and acts as a negative regulator of muscle cells.”
Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats. · BACKGROUND/AIMS
pubmed:15782995:ca9c7c75937e:ca9c7c75937e
Mechanism
Protein engineering changes described include Fc fusion (murine IgG(1) Fc) and elimination of heparan sulfate-binding activity to alter PK characteristics.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“we leveraged protein engineering to modify the PK characteristics of the native molecule by fusing FST315 to a murine IgG(1) Fc and removing the intrinsic heparan sulfate-binding activity of follistatin.”
An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential. · Abstract
pubmed:23249626:bdc9f4ba1d68:bdc9f4ba1d68
Mechanism
The work includes in-depth characterization of pharmacokinetic/pharmacodynamic relationships for native FST315.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“we performed in-depth analyses of the PK/PD relationships of native follistatin-315 (FST315).”
An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential. · Abstract
pubmed:23249626:bdc9f4ba1d68:bdc9f4ba1d68
Mechanism
The described analytical workflow uses immunomagnetic purification and then protein separation/detection by SDS-PAGE and Western blotting using a monoclonal anti-His antibody.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The detection method is based on immunomagnetic purification followed by SDS-PAGE and Western blotting with a monoclonal anti-His antibody.”
Detection of black market follistatin 344. · Abstract
pubmed:31758732:f5e4ca131d7e:f5e4ca131d7e
What has been studied?
What the evidence says.
Study findings
The source attributes multiple functional effects to human follistatin, including antiinflammatory activity, wound healing, and muscle stimulation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Human follistatin is a regulatory glycoprotein with widespread biologic functions, including antiinflammatory activities, wound-healing properties, and muscle-stimulating effects.”
An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential. · Abstract
pubmed:23249626:bdc9f4ba1d68:bdc9f4ba1d68
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Additional research & classification gaps
2 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (2)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The presence of a His-tag enables clear discrimination of the detected protein from endogenous (naturally occurring) follistatin.
Research context only—not evidence of a treatment effect.
- Detection of black market follistatin 344.
Due to the presence of His-tags an unambiguous differentiation from endogenous follistatin is possible.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The immunoprecipitation step uses a polyclonal anti-follistatin antibody.
Research context only—not evidence of a treatment effect.
- Detection of black market follistatin 344.
For immunoprecipitation (IP), a polyclonal anti-follistatin antibody is applied.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
- 27 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (17), assurance_score_below_0.72 (8), current_regulatory_source_required (10), extraction_ambiguity (19), high_risk_requires_regulatory_or_two_independent_sources (10), no_direct_support (18)
- A source-backed introductory overview is not yet available.
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats. ↗
pubmed · published 2005-01-01 · retrieved 2026-09-09T18:02:18Z
- An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential. ↗
pubmed · published 2013-03-01 · retrieved 2026-09-04T19:33:24Z
- Detection of black market follistatin 344. ↗
pubmed · published 2019-11-01 · retrieved 2026-09-09T21:48:18Z
Publication history and provenance
Version 1 · Automated assessment · 2026-09-09T21:48:18Z
d0da7885f37f9b7c80b593ad2047e2ea1ec0623680f8b931a51ae59e6f51ca84